



Examiner: P. Paras, Jr.

Group Art Unit: 1632

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached) is being mailed to Addressee by service of the United States Postal Service addressed to:
Director of Patents
Mail Stop: Patent Applications
P.O. Box 1450
Alexandria, VA 22313-1450

By: Karyn F. Massie
Karyn F. Massie

Date: 6/18/03

INFORMATION DISCLOSURE STATEMENT

Director of Patents
Mail Stop: Patent Applications
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed citations submitted in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56.

Request Under Rule 97(c): A first action on the merits has been issued in this matter, please accept this Information Disclosure Statement under Rule 97(c). The Commissioner is hereby authorized to charge any fee required to the deposit account identified in the attached “Authorization to Pay and Petition for Acceptance of Any Necessary Fees” to cover this fee and proceed to consider this Information Disclosure Statement.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect

is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

PILLSBURY WINTHROP LLP

A handwritten signature in black ink, appearing to read 'R. M. Bedgood', is written over the printed name.

Robert M. Bedgood, Ph.D.
Reg. No 43,488
Tel. No. (858) 509-4065
Fax No. (858) 509-4010
11682 El Camino Real
Suite 200
San Diego, CA 92130-2593
(619) 234-5000



**AUTHORIZATION TO PAY AND PETITION FOR ACCEPTANCE OF
ANY NECESSARY FEES**

If any charges or fees must be paid in connection with the foregoing communication (including but not limited to the payment of an extension fee or issue fee), or if any overpayment is to be refunded in connection with the above-identified application, any such charges or fees, or any such overpayment may be respectively paid out of, or into, our Deposit Account No. 03-3975 under **Reference No.: 029996-0278721.**

Respectfully submitted,
PILLSBURY WINTHROP LLP

Robert M. Bedgood, Ph.D
Reg. No. 43,488
11682 El Camino Real, Suite 200
San Diego, CA 92130

Tel: (858) 509-4065
Fax: (858) 509-4010



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty. Dkt. No.	Client Ref. No.	Matter No.
	029996	0278721
Applicant: Kieffer, T. and Cheung, A.		
Appln. No.: 09/804,409		
Filing Date: March 12, 2001		
Examiner: P. Paras, Jr.		Group Art Unit: 1632

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: June 18, 2003

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	6,503,887 B1	07/2003	DURING			02/22/00

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	BR									
	CR									
	DR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

ER	During, et al. "Peroral gene therapy of lactose intolerance using an andeno-associated virus vector," <u>Nature Medicine</u> , (Oct. 1998), vol. 4, no. 10, pp. 1131-1135.	Y		
FR	During, et al., "An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy," <u>Science</u> , (Feb. 25, 2000), vol. 287 pp. 1453-1460.	Y		
GR	Morsy, et al., "Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse," <u>Gene Therapy</u> , (1998), vol. 5, pp. 8-18.	Y		
HR				
IR				
JR				
KR				

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.